nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—PDE4D—esophageal cancer	0.931	1	CbGaD
Roflumilast—Haematochezia—Capecitabine—esophageal cancer	0.000933	0.047	CcSEcCtD
Roflumilast—PDE4C—G alpha (s) signalling events—GNG7—esophageal cancer	0.000658	0.0133	CbGpPWpGaD
Roflumilast—PDE4B—G Protein Signaling Pathways—GNG7—esophageal cancer	0.000635	0.0128	CbGpPWpGaD
Roflumilast—Infection—Carboplatin—esophageal cancer	0.000616	0.031	CcSEcCtD
Roflumilast—PDE4A—G alpha (s) signalling events—PDE4D—esophageal cancer	0.000573	0.0116	CbGpPWpGaD
Roflumilast—PDE4D—G alpha (s) signalling events—GNG7—esophageal cancer	0.000573	0.0116	CbGpPWpGaD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—GSTO1—esophageal cancer	0.000551	0.0111	CbGpPWpGaD
Roflumilast—PDE4A—G alpha (s) signalling events—GNG7—esophageal cancer	0.000545	0.011	CbGpPWpGaD
Roflumilast—PDE4B—G alpha (s) signalling events—PDE4D—esophageal cancer	0.00053	0.0107	CbGpPWpGaD
Roflumilast—PDE4B—G alpha (s) signalling events—GNG7—esophageal cancer	0.000504	0.0102	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—GSTO1—esophageal cancer	0.000485	0.00979	CbGpPWpGaD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—GNG7—esophageal cancer	0.000479	0.00967	CbGpPWpGaD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—SFN—esophageal cancer	0.000475	0.00959	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—PDE4D—esophageal cancer	0.000444	0.00895	CbGpPWpGaD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—ACTB—esophageal cancer	0.000432	0.00872	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—GNG7—esophageal cancer	0.000422	0.00852	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—SFN—esophageal cancer	0.000419	0.00845	CbGpPWpGaD
Roflumilast—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.000416	0.021	CcSEcCtD
Roflumilast—Renal failure acute—Cisplatin—esophageal cancer	0.000401	0.0202	CcSEcCtD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—ACTB—esophageal cancer	0.000381	0.00768	CbGpPWpGaD
Roflumilast—PDE4D—TSH signaling pathway—RB1—esophageal cancer	0.000369	0.00745	CbGpPWpGaD
Roflumilast—Renal failure acute—Capecitabine—esophageal cancer	0.000295	0.0149	CcSEcCtD
Roflumilast—Atrial fibrillation—Capecitabine—esophageal cancer	0.000288	0.0145	CcSEcCtD
Roflumilast—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00027	0.0136	CcSEcCtD
Roflumilast—Connective tissue disorder—Cisplatin—esophageal cancer	0.000251	0.0127	CcSEcCtD
Roflumilast—Gynaecomastia—Methotrexate—esophageal cancer	0.00025	0.0126	CcSEcCtD
Roflumilast—Gastritis—Capecitabine—esophageal cancer	0.000241	0.0122	CcSEcCtD
Roflumilast—PDE4C—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000241	0.00486	CbGpPWpGaD
Roflumilast—Cardiac disorder—Cisplatin—esophageal cancer	0.000237	0.012	CcSEcCtD
Roflumilast—Influenza—Capecitabine—esophageal cancer	0.000236	0.0119	CcSEcCtD
Roflumilast—Immune system disorder—Cisplatin—esophageal cancer	0.000231	0.0116	CcSEcCtD
Roflumilast—Mediastinal disorder—Cisplatin—esophageal cancer	0.000231	0.0116	CcSEcCtD
Roflumilast—Malnutrition—Cisplatin—esophageal cancer	0.000223	0.0112	CcSEcCtD
Roflumilast—PDE4D—TSH signaling pathway—MYC—esophageal cancer	0.00022	0.00444	CbGpPWpGaD
Roflumilast—Renal failure acute—Methotrexate—esophageal cancer	0.00022	0.0111	CcSEcCtD
Roflumilast—PDE4C—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000219	0.00441	CbGpPWpGaD
Roflumilast—Muscle spasms—Cisplatin—esophageal cancer	0.000214	0.0108	CcSEcCtD
Roflumilast—Weight decreased—Capecitabine—esophageal cancer	0.000213	0.0107	CcSEcCtD
Roflumilast—Pneumonia—Capecitabine—esophageal cancer	0.000211	0.0106	CcSEcCtD
Roflumilast—Infestation—Capecitabine—esophageal cancer	0.00021	0.0106	CcSEcCtD
Roflumilast—Infestation NOS—Capecitabine—esophageal cancer	0.00021	0.0106	CcSEcCtD
Roflumilast—PDE4D—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00021	0.00423	CbGpPWpGaD
Roflumilast—Depression—Capecitabine—esophageal cancer	0.00021	0.0106	CcSEcCtD
Roflumilast—Tremor—Cisplatin—esophageal cancer	0.000209	0.0105	CcSEcCtD
Roflumilast—Ill-defined disorder—Cisplatin—esophageal cancer	0.000207	0.0104	CcSEcCtD
Roflumilast—Urinary tract infection—Capecitabine—esophageal cancer	0.000204	0.0103	CcSEcCtD
Roflumilast—Malaise—Cisplatin—esophageal cancer	0.000201	0.0101	CcSEcCtD
Roflumilast—PDE4C—Signaling Pathways—GDI2—esophageal cancer	0.0002	0.00405	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000199	0.00403	CbGpPWpGaD
Roflumilast—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000199	0.01	CcSEcCtD
Roflumilast—PDE4D—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00019	0.00384	CbGpPWpGaD
Roflumilast—Myalgia—Cisplatin—esophageal cancer	0.00019	0.00955	CcSEcCtD
Roflumilast—Rhinitis—Capecitabine—esophageal cancer	0.000189	0.00953	CcSEcCtD
Roflumilast—Anxiety—Cisplatin—esophageal cancer	0.000189	0.00952	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000188	0.00949	CcSEcCtD
Roflumilast—Discomfort—Cisplatin—esophageal cancer	0.000187	0.00944	CcSEcCtD
Roflumilast—PDE4D—TSH signaling pathway—PIK3CA—esophageal cancer	0.000187	0.00377	CbGpPWpGaD
Roflumilast—Connective tissue disorder—Capecitabine—esophageal cancer	0.000185	0.00934	CcSEcCtD
Roflumilast—PDE4B—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000185	0.00373	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000181	0.00366	CbGpPWpGaD
Roflumilast—Infection—Cisplatin—esophageal cancer	0.000181	0.0091	CcSEcCtD
Roflumilast—Nervous system disorder—Cisplatin—esophageal cancer	0.000178	0.00898	CcSEcCtD
Roflumilast—Skin disorder—Cisplatin—esophageal cancer	0.000177	0.0089	CcSEcCtD
Roflumilast—Cardiac disorder—Capecitabine—esophageal cancer	0.000175	0.00882	CcSEcCtD
Roflumilast—PDE4D—Signaling Pathways—GDI2—esophageal cancer	0.000174	0.00352	CbGpPWpGaD
Roflumilast—Immune system disorder—Capecitabine—esophageal cancer	0.00017	0.00858	CcSEcCtD
Roflumilast—Mediastinal disorder—Capecitabine—esophageal cancer	0.00017	0.00856	CcSEcCtD
Roflumilast—PDE4D—Myometrial Relaxation and Contraction Pathways—NOS3—esophageal cancer	0.000168	0.00338	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000168	0.00338	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—GDI2—esophageal cancer	0.000166	0.00335	CbGpPWpGaD
Roflumilast—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000166	0.00834	CcSEcCtD
Roflumilast—Mental disorder—Capecitabine—esophageal cancer	0.000165	0.00833	CcSEcCtD
Roflumilast—Malnutrition—Capecitabine—esophageal cancer	0.000164	0.00827	CcSEcCtD
Roflumilast—Dysgeusia—Capecitabine—esophageal cancer	0.000161	0.0081	CcSEcCtD
Roflumilast—Back pain—Capecitabine—esophageal cancer	0.000159	0.008	CcSEcCtD
Roflumilast—Decreased appetite—Cisplatin—esophageal cancer	0.000158	0.00796	CcSEcCtD
Roflumilast—Muscle spasms—Capecitabine—esophageal cancer	0.000158	0.00795	CcSEcCtD
Roflumilast—Pneumonia—Methotrexate—esophageal cancer	0.000157	0.00793	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000157	0.00791	CcSEcCtD
Roflumilast—Infestation NOS—Methotrexate—esophageal cancer	0.000156	0.00788	CcSEcCtD
Roflumilast—Infestation—Methotrexate—esophageal cancer	0.000156	0.00788	CcSEcCtD
Roflumilast—Depression—Methotrexate—esophageal cancer	0.000156	0.00786	CcSEcCtD
Roflumilast—PDE4C—GPCR downstream signaling—AKAP13—esophageal cancer	0.000155	0.00313	CbGpPWpGaD
Roflumilast—Tremor—Capecitabine—esophageal cancer	0.000154	0.00775	CcSEcCtD
Roflumilast—PDE4B—Signaling Pathways—GDI2—esophageal cancer	0.000154	0.0031	CbGpPWpGaD
Roflumilast—Ill-defined disorder—Capecitabine—esophageal cancer	0.000152	0.00768	CcSEcCtD
Roflumilast—Feeling abnormal—Cisplatin—esophageal cancer	0.00015	0.00755	CcSEcCtD
Roflumilast—Malaise—Capecitabine—esophageal cancer	0.000148	0.00746	CcSEcCtD
Roflumilast—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000148	0.00745	CcSEcCtD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—NOS3—esophageal cancer	0.000148	0.00298	CbGpPWpGaD
Roflumilast—Vertigo—Capecitabine—esophageal cancer	0.000148	0.00743	CcSEcCtD
Roflumilast—Palpitations—Capecitabine—esophageal cancer	0.000145	0.00731	CcSEcCtD
Roflumilast—PDE4C—Signaling Pathways—KMT2D—esophageal cancer	0.000145	0.00292	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PDE4D—esophageal cancer	0.000142	0.00286	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—AKAP13—esophageal cancer	0.000141	0.00284	CbGpPWpGaD
Roflumilast—Myalgia—Capecitabine—esophageal cancer	0.00014	0.00704	CcSEcCtD
Roflumilast—Anxiety—Capecitabine—esophageal cancer	0.000139	0.00702	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000139	0.00699	CcSEcCtD
Roflumilast—Discomfort—Capecitabine—esophageal cancer	0.000138	0.00696	CcSEcCtD
Roflumilast—PDE4D—GPCR downstream signaling—AKAP13—esophageal cancer	0.000135	0.00273	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—GNG7—esophageal cancer	0.000135	0.00272	CbGpPWpGaD
Roflumilast—Hypersensitivity—Cisplatin—esophageal cancer	0.000134	0.00675	CcSEcCtD
Roflumilast—Infection—Capecitabine—esophageal cancer	0.000133	0.00671	CcSEcCtD
Roflumilast—Nervous system disorder—Capecitabine—esophageal cancer	0.000131	0.00662	CcSEcCtD
Roflumilast—Asthenia—Cisplatin—esophageal cancer	0.00013	0.00657	CcSEcCtD
Roflumilast—Cardiac disorder—Methotrexate—esophageal cancer	0.00013	0.00657	CcSEcCtD
Roflumilast—Skin disorder—Capecitabine—esophageal cancer	0.00013	0.00656	CcSEcCtD
Roflumilast—PDE4C—Signaling Pathways—ADCYAP1—esophageal cancer	0.000129	0.00261	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PDE4D—esophageal cancer	0.000129	0.0026	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—AKAP13—esophageal cancer	0.000129	0.00259	CbGpPWpGaD
Roflumilast—Immune system disorder—Methotrexate—esophageal cancer	0.000127	0.00639	CcSEcCtD
Roflumilast—Mediastinal disorder—Methotrexate—esophageal cancer	0.000127	0.00638	CcSEcCtD
Roflumilast—PDE4D—Signaling Pathways—KMT2D—esophageal cancer	0.000126	0.00255	CbGpPWpGaD
Roflumilast—Diarrhoea—Cisplatin—esophageal cancer	0.000124	0.00627	CcSEcCtD
Roflumilast—Mental disorder—Methotrexate—esophageal cancer	0.000123	0.0062	CcSEcCtD
Roflumilast—PDE4D—Signaling by GPCR—AKAP13—esophageal cancer	0.000123	0.00248	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—GNG7—esophageal cancer	0.000123	0.00247	CbGpPWpGaD
Roflumilast—Malnutrition—Methotrexate—esophageal cancer	0.000122	0.00616	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000122	0.00615	CcSEcCtD
Roflumilast—Insomnia—Capecitabine—esophageal cancer	0.000121	0.00611	CcSEcCtD
Roflumilast—PDE4A—Signaling Pathways—KMT2D—esophageal cancer	0.00012	0.00242	CbGpPWpGaD
Roflumilast—Dysgeusia—Methotrexate—esophageal cancer	0.00012	0.00603	CcSEcCtD
Roflumilast—PDE4B—GPCR downstream signaling—AKAP13—esophageal cancer	0.000119	0.0024	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CXCL2—esophageal cancer	0.000119	0.0024	CbGpPWpGaD
Roflumilast—Back pain—Methotrexate—esophageal cancer	0.000118	0.00596	CcSEcCtD
Roflumilast—PDE4C—Signaling Pathways—WWOX—esophageal cancer	0.000118	0.00238	CbGpPWpGaD
Roflumilast—Dyspepsia—Capecitabine—esophageal cancer	0.000118	0.00594	CcSEcCtD
Roflumilast—PDE4A—GPCR downstream signaling—PDE4D—esophageal cancer	0.000118	0.00237	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—GNG7—esophageal cancer	0.000117	0.00237	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—AKAP13—esophageal cancer	0.000117	0.00236	CbGpPWpGaD
Roflumilast—Decreased appetite—Capecitabine—esophageal cancer	0.000116	0.00587	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000116	0.00583	CcSEcCtD
Roflumilast—Vomiting—Cisplatin—esophageal cancer	0.000116	0.00582	CcSEcCtD
Roflumilast—Fatigue—Capecitabine—esophageal cancer	0.000116	0.00582	CcSEcCtD
Roflumilast—Rash—Cisplatin—esophageal cancer	0.000115	0.00577	CcSEcCtD
Roflumilast—Constipation—Capecitabine—esophageal cancer	0.000115	0.00577	CcSEcCtD
Roflumilast—Dermatitis—Cisplatin—esophageal cancer	0.000115	0.00577	CcSEcCtD
Roflumilast—Ill-defined disorder—Methotrexate—esophageal cancer	0.000113	0.00571	CcSEcCtD
Roflumilast—PDE4D—Signaling Pathways—ADCYAP1—esophageal cancer	0.000112	0.00227	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—FKBP1A—esophageal cancer	0.000112	0.00227	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—GNG7—esophageal cancer	0.000112	0.00226	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KMT2D—esophageal cancer	0.000111	0.00224	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—ANXA1—esophageal cancer	0.000111	0.00223	CbGpPWpGaD
Roflumilast—Feeling abnormal—Capecitabine—esophageal cancer	0.00011	0.00556	CcSEcCtD
Roflumilast—Malaise—Methotrexate—esophageal cancer	0.00011	0.00555	CcSEcCtD
Roflumilast—Vertigo—Methotrexate—esophageal cancer	0.00011	0.00553	CcSEcCtD
Roflumilast—PDE4C—Signaling Pathways—WIF1—esophageal cancer	0.00011	0.00222	CbGpPWpGaD
Roflumilast—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00011	0.00552	CcSEcCtD
Roflumilast—PDE4B—GPCR downstream signaling—PDE4D—esophageal cancer	0.000109	0.0022	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—AKAP13—esophageal cancer	0.000108	0.00218	CbGpPWpGaD
Roflumilast—Nausea—Cisplatin—esophageal cancer	0.000108	0.00544	CcSEcCtD
Roflumilast—PDE4C—Signaling by GPCR—CXCL2—esophageal cancer	0.000108	0.00218	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—SST—esophageal cancer	0.000108	0.00217	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000107	0.00216	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PDE4D—esophageal cancer	0.000107	0.00216	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—GNG7—esophageal cancer	0.000107	0.00215	CbGpPWpGaD
Roflumilast—Urticaria—Capecitabine—esophageal cancer	0.000106	0.00536	CcSEcCtD
Roflumilast—Abdominal pain—Capecitabine—esophageal cancer	0.000106	0.00534	CcSEcCtD
Roflumilast—PDE4C—GPCR downstream signaling—GHRL—esophageal cancer	0.000105	0.00212	CbGpPWpGaD
Roflumilast—Myalgia—Methotrexate—esophageal cancer	0.000104	0.00524	CcSEcCtD
Roflumilast—PDE4D—GPCR downstream signaling—CXCL2—esophageal cancer	0.000104	0.00209	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—GNG7—esophageal cancer	0.000103	0.00209	CbGpPWpGaD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000103	0.00521	CcSEcCtD
Roflumilast—PDE4D—Signaling Pathways—WWOX—esophageal cancer	0.000103	0.00208	CbGpPWpGaD
Roflumilast—Discomfort—Methotrexate—esophageal cancer	0.000103	0.00518	CcSEcCtD
Roflumilast—PDE4A—Signaling by GPCR—GNG7—esophageal cancer	0.000102	0.00205	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CSNK1A1—esophageal cancer	0.000101	0.00205	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—ANXA1—esophageal cancer	0.0001	0.00203	CbGpPWpGaD
Roflumilast—Infection—Methotrexate—esophageal cancer	9.91e-05	0.00499	CcSEcCtD
Roflumilast—PDE4B—Signaling Pathways—ADCYAP1—esophageal cancer	9.9e-05	0.002	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PDE4D—esophageal cancer	9.88e-05	0.00199	CbGpPWpGaD
Roflumilast—Hypersensitivity—Capecitabine—esophageal cancer	9.87e-05	0.00497	CcSEcCtD
Roflumilast—PDE4A—GPCR downstream signaling—CXCL2—esophageal cancer	9.85e-05	0.00199	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—WWOX—esophageal cancer	9.79e-05	0.00198	CbGpPWpGaD
Roflumilast—Nervous system disorder—Methotrexate—esophageal cancer	9.78e-05	0.00493	CcSEcCtD
Roflumilast—PDE4D—Signaling Pathways—FKBP1A—esophageal cancer	9.78e-05	0.00197	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—SST—esophageal cancer	9.77e-05	0.00197	CbGpPWpGaD
Roflumilast—Skin disorder—Methotrexate—esophageal cancer	9.69e-05	0.00488	CcSEcCtD
Roflumilast—PDE4D—GPCR downstream signaling—ANXA1—esophageal cancer	9.62e-05	0.00194	CbGpPWpGaD
Roflumilast—Asthenia—Capecitabine—esophageal cancer	9.61e-05	0.00484	CcSEcCtD
Roflumilast—PDE4D—Signaling Pathways—WIF1—esophageal cancer	9.56e-05	0.00193	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—GHRL—esophageal cancer	9.52e-05	0.00192	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PFN1—esophageal cancer	9.48e-05	0.00191	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CXCL2—esophageal cancer	9.4e-05	0.0019	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—GNG7—esophageal cancer	9.4e-05	0.0019	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—SST—esophageal cancer	9.36e-05	0.00189	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FKBP1A—esophageal cancer	9.31e-05	0.00188	CbGpPWpGaD
Roflumilast—Diarrhoea—Capecitabine—esophageal cancer	9.17e-05	0.00462	CcSEcCtD
Roflumilast—PDE4A—GPCR downstream signaling—ANXA1—esophageal cancer	9.16e-05	0.00185	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—GHRL—esophageal cancer	9.12e-05	0.00184	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CXCL2—esophageal cancer	9.12e-05	0.00184	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—WIF1—esophageal cancer	9.1e-05	0.00184	CbGpPWpGaD
Roflumilast—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.09e-05	0.00458	CcSEcCtD
Roflumilast—PDE4B—Signaling Pathways—WWOX—esophageal cancer	9.06e-05	0.00183	CbGpPWpGaD
Roflumilast—Insomnia—Methotrexate—esophageal cancer	9.02e-05	0.00455	CcSEcCtD
Roflumilast—PDE4A—Signaling by GPCR—CXCL2—esophageal cancer	8.95e-05	0.00181	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—SST—esophageal cancer	8.91e-05	0.0018	CbGpPWpGaD
Roflumilast—Dizziness—Capecitabine—esophageal cancer	8.86e-05	0.00446	CcSEcCtD
Roflumilast—PDE4D—Signaling Pathways—CSNK1A1—esophageal cancer	8.82e-05	0.00178	CbGpPWpGaD
Roflumilast—Dyspepsia—Methotrexate—esophageal cancer	8.78e-05	0.00442	CcSEcCtD
Roflumilast—PDE4D—Signaling by GPCR—ANXA1—esophageal cancer	8.74e-05	0.00176	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—GHRL—esophageal cancer	8.68e-05	0.00175	CbGpPWpGaD
Roflumilast—Decreased appetite—Methotrexate—esophageal cancer	8.67e-05	0.00437	CcSEcCtD
Roflumilast—PDE4B—Signaling Pathways—FKBP1A—esophageal cancer	8.61e-05	0.00174	CbGpPWpGaD
Roflumilast—Gastrointestinal disorder—Methotrexate—esophageal cancer	8.61e-05	0.00434	CcSEcCtD
Roflumilast—Fatigue—Methotrexate—esophageal cancer	8.6e-05	0.00433	CcSEcCtD
Roflumilast—Vomiting—Capecitabine—esophageal cancer	8.52e-05	0.00429	CcSEcCtD
Roflumilast—PDE4C—Signaling Pathways—ELMO1—esophageal cancer	8.51e-05	0.00172	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—SST—esophageal cancer	8.5e-05	0.00172	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—ANXA1—esophageal cancer	8.48e-05	0.00171	CbGpPWpGaD
Roflumilast—Rash—Capecitabine—esophageal cancer	8.45e-05	0.00426	CcSEcCtD
Roflumilast—Dermatitis—Capecitabine—esophageal cancer	8.44e-05	0.00425	CcSEcCtD
Roflumilast—PDE4B—Signaling Pathways—WIF1—esophageal cancer	8.42e-05	0.0017	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CSNK1A1—esophageal cancer	8.4e-05	0.0017	CbGpPWpGaD
Roflumilast—Headache—Capecitabine—esophageal cancer	8.4e-05	0.00423	CcSEcCtD
Roflumilast—PDE4C—Signaling Pathways—AKAP13—esophageal cancer	8.32e-05	0.00168	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—ANXA1—esophageal cancer	8.32e-05	0.00168	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—GHRL—esophageal cancer	8.28e-05	0.00167	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CXCL2—esophageal cancer	8.28e-05	0.00167	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PFN1—esophageal cancer	8.25e-05	0.00167	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—SST—esophageal cancer	8.24e-05	0.00166	CbGpPWpGaD
Roflumilast—Feeling abnormal—Methotrexate—esophageal cancer	8.22e-05	0.00414	CcSEcCtD
Roflumilast—Gastrointestinal pain—Methotrexate—esophageal cancer	8.16e-05	0.00411	CcSEcCtD
Roflumilast—PDE4A—Signaling by GPCR—SST—esophageal cancer	8.09e-05	0.00163	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—GHRL—esophageal cancer	8.03e-05	0.00162	CbGpPWpGaD
Roflumilast—Nausea—Capecitabine—esophageal cancer	7.96e-05	0.00401	CcSEcCtD
Roflumilast—Urticaria—Methotrexate—esophageal cancer	7.93e-05	0.00399	CcSEcCtD
Roflumilast—Abdominal pain—Methotrexate—esophageal cancer	7.89e-05	0.00397	CcSEcCtD
Roflumilast—PDE4A—Signaling by GPCR—GHRL—esophageal cancer	7.89e-05	0.00159	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PFN1—esophageal cancer	7.85e-05	0.00159	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CSNK1A1—esophageal cancer	7.77e-05	0.00157	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—ANXA1—esophageal cancer	7.7e-05	0.00155	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—HIST1H2BM—esophageal cancer	7.68e-05	0.00155	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PDE4D—esophageal cancer	7.61e-05	0.00154	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—SST—esophageal cancer	7.49e-05	0.00151	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ELMO1—esophageal cancer	7.41e-05	0.0015	CbGpPWpGaD
Roflumilast—Hypersensitivity—Methotrexate—esophageal cancer	7.35e-05	0.0037	CcSEcCtD
Roflumilast—PDE4B—Signaling by GPCR—GHRL—esophageal cancer	7.3e-05	0.00147	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PFN1—esophageal cancer	7.27e-05	0.00147	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AKAP13—esophageal cancer	7.24e-05	0.00146	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—GNG7—esophageal cancer	7.24e-05	0.00146	CbGpPWpGaD
Roflumilast—Asthenia—Methotrexate—esophageal cancer	7.16e-05	0.00361	CcSEcCtD
Roflumilast—PDE4A—Signaling Pathways—ELMO1—esophageal cancer	7.06e-05	0.00142	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AKAP13—esophageal cancer	6.9e-05	0.00139	CbGpPWpGaD
Roflumilast—Diarrhoea—Methotrexate—esophageal cancer	6.83e-05	0.00344	CcSEcCtD
Roflumilast—PDE4C—Signaling Pathways—XIAP—esophageal cancer	6.78e-05	0.00137	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HIST1H2BM—esophageal cancer	6.69e-05	0.00135	CbGpPWpGaD
Roflumilast—Dizziness—Methotrexate—esophageal cancer	6.6e-05	0.00332	CcSEcCtD
Roflumilast—PDE4B—Signaling Pathways—ELMO1—esophageal cancer	6.53e-05	0.00132	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CTNNA1—esophageal cancer	6.42e-05	0.00129	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AKAP13—esophageal cancer	6.38e-05	0.00129	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CXCL2—esophageal cancer	6.38e-05	0.00129	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HIST1H2BM—esophageal cancer	6.36e-05	0.00128	CbGpPWpGaD
Roflumilast—Vomiting—Methotrexate—esophageal cancer	6.34e-05	0.0032	CcSEcCtD
Roflumilast—PDE4A—Signaling Pathways—PDE4D—esophageal cancer	6.31e-05	0.00127	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—GNG7—esophageal cancer	6.3e-05	0.00127	CbGpPWpGaD
Roflumilast—Rash—Methotrexate—esophageal cancer	6.29e-05	0.00317	CcSEcCtD
Roflumilast—Dermatitis—Methotrexate—esophageal cancer	6.28e-05	0.00317	CcSEcCtD
Roflumilast—Headache—Methotrexate—esophageal cancer	6.25e-05	0.00315	CcSEcCtD
Roflumilast—PDE4A—Signaling Pathways—GNG7—esophageal cancer	6e-05	0.00121	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PSME1—esophageal cancer	5.96e-05	0.0012	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PSME2—esophageal cancer	5.96e-05	0.0012	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ANXA1—esophageal cancer	5.93e-05	0.0012	CbGpPWpGaD
Roflumilast—Nausea—Methotrexate—esophageal cancer	5.93e-05	0.00299	CcSEcCtD
Roflumilast—PDE4D—Signaling Pathways—XIAP—esophageal cancer	5.91e-05	0.00119	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HIST1H2BM—esophageal cancer	5.89e-05	0.00119	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PDE4D—esophageal cancer	5.84e-05	0.00118	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SST—esophageal cancer	5.77e-05	0.00116	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—XIAP—esophageal cancer	5.62e-05	0.00113	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NOTCH3—esophageal cancer	5.62e-05	0.00113	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—GHRL—esophageal cancer	5.62e-05	0.00113	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CTNNA1—esophageal cancer	5.58e-05	0.00113	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CXCL2—esophageal cancer	5.55e-05	0.00112	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—GNG7—esophageal cancer	5.55e-05	0.00112	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—FBXW7—esophageal cancer	5.53e-05	0.00112	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CTNNA1—esophageal cancer	5.32e-05	0.00107	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CXCL2—esophageal cancer	5.29e-05	0.00107	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—XIAP—esophageal cancer	5.2e-05	0.00105	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PSME1—esophageal cancer	5.19e-05	0.00105	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PSME2—esophageal cancer	5.19e-05	0.00105	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ANXA1—esophageal cancer	5.16e-05	0.00104	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NOTCH2—esophageal cancer	5.04e-05	0.00102	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SST—esophageal cancer	5.02e-05	0.00101	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PSME2—esophageal cancer	4.94e-05	0.000997	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PSME1—esophageal cancer	4.94e-05	0.000997	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CTNNA1—esophageal cancer	4.92e-05	0.000993	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ANXA1—esophageal cancer	4.91e-05	0.000992	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—GHRL—esophageal cancer	4.89e-05	0.000988	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NOTCH3—esophageal cancer	4.89e-05	0.000988	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CXCL2—esophageal cancer	4.89e-05	0.000987	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—FBXW7—esophageal cancer	4.81e-05	0.000972	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SST—esophageal cancer	4.78e-05	0.000965	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—GHRL—esophageal cancer	4.66e-05	0.00094	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NOTCH3—esophageal cancer	4.66e-05	0.00094	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FBXW7—esophageal cancer	4.58e-05	0.000925	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PSME2—esophageal cancer	4.57e-05	0.000922	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PSME1—esophageal cancer	4.57e-05	0.000922	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ANXA1—esophageal cancer	4.55e-05	0.000918	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TGFBR2—esophageal cancer	4.47e-05	0.000903	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SST—esophageal cancer	4.42e-05	0.000893	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NOTCH2—esophageal cancer	4.39e-05	0.000886	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NOTCH3—esophageal cancer	4.31e-05	0.00087	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—GHRL—esophageal cancer	4.31e-05	0.00087	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FBXW7—esophageal cancer	4.24e-05	0.000856	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SMAD4—esophageal cancer	4.23e-05	0.000855	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NOTCH2—esophageal cancer	4.18e-05	0.000843	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TGFBR2—esophageal cancer	3.89e-05	0.000786	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NOTCH2—esophageal cancer	3.87e-05	0.00078	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TGFBR2—esophageal cancer	3.71e-05	0.000748	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SMAD4—esophageal cancer	3.69e-05	0.000744	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SMAD4—esophageal cancer	3.51e-05	0.000708	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—HIF1A—esophageal cancer	3.46e-05	0.000699	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TGFBR2—esophageal cancer	3.43e-05	0.000692	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KDR—esophageal cancer	3.31e-05	0.000669	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SMAD4—esophageal cancer	3.25e-05	0.000655	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NOTCH1—esophageal cancer	3.12e-05	0.00063	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HIF1A—esophageal cancer	3.02e-05	0.000609	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KDR—esophageal cancer	2.88e-05	0.000582	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HIF1A—esophageal cancer	2.87e-05	0.000579	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CREBBP—esophageal cancer	2.83e-05	0.000571	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—EGFR—esophageal cancer	2.78e-05	0.000561	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KDR—esophageal cancer	2.75e-05	0.000554	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NOTCH1—esophageal cancer	2.72e-05	0.000548	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PIK3CA—esophageal cancer	2.66e-05	0.000536	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HIF1A—esophageal cancer	2.66e-05	0.000536	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NOTCH1—esophageal cancer	2.59e-05	0.000522	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KDR—esophageal cancer	2.54e-05	0.000513	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NOS3—esophageal cancer	2.53e-05	0.000511	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CREBBP—esophageal cancer	2.46e-05	0.000497	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—EGFR—esophageal cancer	2.42e-05	0.000489	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PIK3CA—esophageal cancer	2.41e-05	0.000487	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NOTCH1—esophageal cancer	2.39e-05	0.000483	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ERBB2—esophageal cancer	2.37e-05	0.000478	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CREBBP—esophageal cancer	2.34e-05	0.000473	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PIK3CA—esophageal cancer	2.31e-05	0.000467	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—EGFR—esophageal cancer	2.3e-05	0.000465	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NOS3—esophageal cancer	2.21e-05	0.000445	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PIK3CA—esophageal cancer	2.2e-05	0.000445	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CREBBP—esophageal cancer	2.17e-05	0.000438	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—EGFR—esophageal cancer	2.13e-05	0.00043	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PIK3CA—esophageal cancer	2.1e-05	0.000424	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NOS3—esophageal cancer	2.1e-05	0.000424	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCND1—esophageal cancer	2.09e-05	0.000423	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ERBB2—esophageal cancer	2.06e-05	0.000416	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PIK3CA—esophageal cancer	2.04e-05	0.000411	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CDKN1A—esophageal cancer	2.03e-05	0.000409	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PIK3CA—esophageal cancer	2e-05	0.000404	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ERBB2—esophageal cancer	1.96e-05	0.000396	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NOS3—esophageal cancer	1.94e-05	0.000392	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EP300—esophageal cancer	1.93e-05	0.000389	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CA—esophageal cancer	1.85e-05	0.000373	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCND1—esophageal cancer	1.82e-05	0.000368	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ERBB2—esophageal cancer	1.82e-05	0.000367	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CDKN1A—esophageal cancer	1.76e-05	0.000356	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCND1—esophageal cancer	1.73e-05	0.00035	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MYC—esophageal cancer	1.68e-05	0.000339	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CDKN1A—esophageal cancer	1.68e-05	0.000339	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EP300—esophageal cancer	1.68e-05	0.000339	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EGFR—esophageal cancer	1.64e-05	0.000332	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCND1—esophageal cancer	1.61e-05	0.000324	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EP300—esophageal cancer	1.6e-05	0.000322	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CDKN1A—esophageal cancer	1.55e-05	0.000313	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EP300—esophageal cancer	1.48e-05	0.000298	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MYC—esophageal cancer	1.46e-05	0.000295	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EGFR—esophageal cancer	1.43e-05	0.000289	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CA—esophageal cancer	1.43e-05	0.000288	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MYC—esophageal cancer	1.39e-05	0.000281	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TP53—esophageal cancer	1.38e-05	0.000278	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EGFR—esophageal cancer	1.36e-05	0.000275	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MYC—esophageal cancer	1.29e-05	0.00026	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EGFR—esophageal cancer	1.26e-05	0.000254	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CA—esophageal cancer	1.24e-05	0.000251	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TP53—esophageal cancer	1.2e-05	0.000242	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CA—esophageal cancer	1.18e-05	0.000238	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TP53—esophageal cancer	1.14e-05	0.000231	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CA—esophageal cancer	1.09e-05	0.000221	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TP53—esophageal cancer	1.06e-05	0.000213	CbGpPWpGaD
